Navigation Links
Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
Date:10/21/2008

er's disease.

About Alzheimer's Disease

AD is a progressive brain disorder that gradually destroys a person's memory and ability to learn, reason, make judgments, communicate and carry out daily activities. AD is characterised by the progressive destruction of brain cells leading to a decline in mental function and eventually, Alzheimer patients need complete care.

Current estimates show that approximately four million people suffer from AD in the US and 15 million worldwide. Most available treatments produce an increase of the acetylcholine levels by inhibiting AChE, the enzyme responsible for its breakdown. Currently used therapies have significant side-effects which can occur with a frequency of up to 50% for nausea for instance. These treatments generally require complicated titration schemes in order to minimise these cholinergic side-effects, which is a challenge when dealing with memory deficient patients.

An AChE inhibitor with a better tolerance profile than existing treatments and with an easierdosing schedule could improve patient compliance and therefore optimise the patient's treatment.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. It develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com'/>"/>

SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
2. Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. First Town Hall Meeting on Inequities in Clinical Trials to Take Place at the Harlem Hospital Center on October 20
6. Perceptive Informatics Improves Clinical Trial Management With Enhanced TrialWorks(R) Solution
7. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
8. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
9. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
10. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
11. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015 Semler Scientific, Inc. (Nasdaq: ... that develops, manufactures and markets products that assist healthcare ... reported financial results for the first quarter ended March ... of 2015, Semler reported continued progress with year over ... revenue growth of 14%," said Doug Murphy-Chutorian , ...
(Date:5/1/2015)...  Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ... the results of the Phase 3 Rocket 1 trail ... failing to meet its end points, compelling data from ... future studies. An analyst report on AERI ... review, analyst summary, valuation, and recommendation can be viewed ...
(Date:4/30/2015)... 30, 2015  Accuray Incorporated (Nasdaq: ARAY ... agreement with MIM Software Inc. to further develop ... and CyberKnife ® product portfolios. The new software ... This is Accuray,s second collaboration with MIM; the ... first iPad-based treatment plan review capability, PlanTouch™. ...
Breaking Medicine Technology:Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3
(Date:5/3/2015)... NuevaCare announced today that it will ... seminars. The first event will take place on Wednesday, ... to be held at The Magnolia of Millbrae. The ... during the Dementia Conference to be held at the ... an excellent opportunity to learn about the MnemeTherapy® approach ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... event today, Saturday, May 2nd at the MGM Grand Garden ... able to secure tickets for both the actual fight and ... have wanted for more than five years was finally been ... step inside the ring to fight Manny “Pac-Man” Pacquiao in ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 We are ... The Delray Recovery Center as one of the Top ... known in the addiction treatment field for their ethics ... to innovate and to continue their educational efforts. The ... workplace environment, never forgetting their purpose – to help ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand ... offer its new healthcare insurance to individuals and small ... Insurance System is the nation’s first health insurance system ... ZOOM+ Personal Health Insurance was ZoomCare’s first such filing ... subject to review and regulation by the Oregon Insurance ...
(Date:5/1/2015)... Jusuru International has been awarded the prestigious ... its flagship nutritional supplement, Liquid BioCell™ Life, and the ... new logo, new packaging, new products, and new messaging. ... identify and promote programs that serve as examples of ... Jusuru International for their outstanding accomplishments and contributions to ...
Breaking Medicine News(10 mins):Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5
... , , , , , , ... Medical,International Limited (NYSE: MR ), a leading developer, ... at its annual general meeting of shareholders held in Hong ... the meeting, Mindray Medical International,s shareholders approved the,re-election of directors ...
... causes more pain than vodka, study finds , FRIDAY, Dec. ... a common indulgence -- and nasty hangovers a common consequence. ... lighter-colored beverages, they might feel a little better the next ... contain more toxic properties that provoke more painful hangovers than ...
... , , , NEWPORT BEACH, Calif., Dec. 18 ... announced today that it has given notice that it is ... Cumulative Convertible Preferred Stock ("Series B Preferred Stock") (NHP-PB - ... price per share of $103.875 plus an amount equal to ...
... thoughts may help explain interpersonal problems , FRIDAY, Dec. ... are less active than expected when they,re engaged in ... difficulties, say British researchers. , Using functional MRI, they ... whom had autism, while they were asked questions about ...
... CentraCare president is new chair , ST. PAUL, Minn., Dec. ... systems, recently elected or re-elected the following members to its board for ... Chair - Terence Pladson, M.D., president, CentraCare Health System, ... CEO, Queen of Peace Hospital, New Prague, Secretary/treasurer - ...
... , , HOUSTON, Dec. 18 ... largest provider of deathcare products and services in North America, ... has extended the expiry time of its offer (the "Offer") ... and outstanding common shares in the capital of Keystone North ...
Cached Medicine News:Health News:Mindray Medical International Limited Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting 2Health News:For a Lighter Hangover, Avoid Darker Drinks 2Health News:For a Lighter Hangover, Avoid Darker Drinks 3Health News:For a Lighter Hangover, Avoid Darker Drinks 4Health News:Nationwide Health Properties, Inc. Announces the Redemption of All Outstanding Shares of 7.75% Series B Cumulative Convertible Preferred Stock 2Health News:Brain Imaging Sheds Light on Social Woes Related to Autism 2Health News:Minnesota Hospital Association Elects, Re-Elects Members to Board 2Health News:Service Corporation International Extends Offer for Keystone North America Inc. 2Health News:Service Corporation International Extends Offer for Keystone North America Inc. 3
... low profile implantable bipolar fixed screw-in ... either the atrium or the ventricle. ... a screwdriver shape stylet which is ... ring tip and fixation screw are ...
... are implantable bipolar extendable/retractable screw-in permanent ... the atrium or the ventricle. The ... extended or retracted by turning the ... an anti-chattering mechanism for steady pacing ...
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Used to occupy an empty hole which is not being used in an implantablepacemaker header....
Medicine Products: